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ease, prion diseases, type II diabetes, and others. Although the molecular factors responsible for amyloid pathologies have not
been deciphered, interactions of misfolded proteins with cell membranes appear to play important roles in these disorders.
Despite increasing evidence for the involvement of membranes in amyloid-mediated cytotoxicity, the pursuit for therapeutic stra-
tegies has focused on preventing self-assembly of the proteins comprising the amyloid plaques. Here we present an investiga-
tion of the impact of fibrillation modulators upon membrane interactions of b2-microglobulin (b2m) fibrils. The experiments reveal
that polyphenols (epigallocatechin gallate, bromophenol blue, and resveratrol) and glycosaminoglycans (heparin and heparin
disaccharide) differentially affect membrane interactions of b2m fibrils measured by dye-release experiments, fluorescence
anisotropy of labeled lipid, and confocal and cryo-electron microscopies. Interestingly, whereas epigallocatechin gallate and
heparin prevent membrane damage as judged by these assays, the other compounds tested had little, or no, effect. The results
suggest a new dimension to the biological impact of fibrillation modulators that involves interference with membrane interactions
of amyloid species, adding to contemporary strategies for combating amyloid diseases that focus on disruption or remodeling of
amyloid aggregates.INTRODUCTIONThe transformation of soluble proteins into amyloid fibrils
deposited in different organs and tissues is a hallmark
of devastating medical disorders, including Alzheimer’s
disease, Parkinson’s disease, type II diabetes, and others
(1,2). Although the presence of fibrillar aggregates appears
to be a universal phenomenon in amyloid diseases, the rela-
tionships among amyloid formation, disease progression,
and pathogenicity remain unclear.
Amyloid plaques are commonly found extracellularly,
often associated with external membrane surfaces (3),
although intracellular amyloid deposits are involved in
several human disorders (3). A number of recent studies
have linked the cytotoxicity of amyloid species with their
membrane activity, suggesting that only toxic aggregates
bind and disrupt lipid membranes, whereas benign con-
formers remain inert (4,5). There is an ongoing scientific
debate, however, about the nature of pathogenic species. It
was initially postulated that large insoluble amyloid plaques
are the main culprits of the observed pathological conditions
(6). This hypothesis was challenged by findings showing
that small oligomeric intermediates, rather than the end-
products of the aggregation pathway, represent the primary
factors leading to cell damage and death (7,8). This conceptSubmitted March 15, 2013, and accepted for publication June 4, 2013.
6Tania Sheynis and Anat Friediger contributed equally to this work.
*Correspondence: s.e.radford@leeds.ac.uk or razj@bgu.ac.il
Wei-Feng Xue’s current address is School of Biosciences, University of
Kent, Canterbury, Kent CT2 7NZ, UK.
Editor: Elizabeth Rhoades.
 2013 by the Biophysical Society
0006-3495/13/08/0745/11
Open access under CC BY license.was taken further by the suggestion that rapid fibrillation
may provide a protective mechanism through formation of
inert deposits that reduce the population of transient oligo-
meric species (9). By contrast with these findings, several
recent studies have implicated amyloid fibrils themselves
in amyloid diseases. Specifically, fibrils derived from
various amyloidogenic proteins have been shown to func-
tion as cytotoxic substances that readily bind and permeabi-
lize lipid membranes (10–12), a process that is enhanced by
fibril fragmentation (11,13). Preformed amyloid fibrils have
also been shown to be internalized by cultured cells and to
recruit cytosolic cellular proteins into growing amyloid
assemblies (14). In vivo studies demonstrated that mature
fibrils induce propagation of amyloidosis and the corre-
sponding pathology in wild-type mouse (15) and human
brains (16) through intercellular transmission. Finally,
fibrils can be regarded as a source of toxic entities capable
of releasing oligomeric species (17), particularly during
interaction with lipids (18).
Directly related to the above observations, the mecha-
nistic aspects of amyloid-protein interactions with cellular
membranes have been the focus of intense experimental
work in recent years (19,20). However, whereas lipid- and
membrane-interactions of misfolded proteins appear to be
closely related to amyloid cytotoxicity (4,5), development
of therapeutic remedies has been directed in a large part
toward substances that interfere with the aggregation pro-
cesses of amyloid precursors into higher-order oligomeric
species. Aggregation inhibitor screens have resulted in the
discovery of numerous and diverse molecular leads, somehttp://dx.doi.org/10.1016/j.bpj.2013.06.015
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cellular toxicity (21–23). Polyphenols, such as resveratrol
(found in red grape skins and seeds) (24,25) and epigalloca-
techin gallate (EGCG, a component of green tea) (26,27)
have been among the most widely studied inhibitors of
amyloid cytotoxicity and fibril assembly modulators. These
molecules have been shown to remodel toxic oligomers into
large nontoxic aggregates (28–30) as well as to promote
fibril disassembly (29,30). Another group of fibrillation
modulators includes glycosaminoglycans (GAGs), anionic
polysaccharides widely expressed in different tissue types
(31). Heparin, an abundant member of the GAG family
(31), has been demonstrated to modulate the fibrillation
route and the associated toxicity of various amyloidogenic
sequences (32,33). In addition, ionic chelators (21,34),
molecular chaperones (35), b-sheet breaking peptides (22),
antibodies (23), g-bodies (36), and polymeric nanoparticles
conjugated to functional groups (34,37) have all been used
to modulate the course of fibril assembly.
Despite the apparent relationship between membrane
interactions of amyloid assemblies and cellular toxicity,
the impact of aggregation inhibitors upon membrane activ-
ity and lipid-binding properties of amyloid species has
been addressed only sparingly (25,38). Here we investigate
the relationships among the effects of different polyphenols
and the glycosaminoglycans heparin and heparin disaccha-
ride on membrane interactions of amyloid fibrils formed
in vitro from b2-microglobulin (b2m). b2m, the noncova-
lently bound light chain of the MHC-class I complex
(39), forms insoluble fibrillar amyloid aggregates that are
intimately involved in progression of dialysis-related
amyloidosis (11,40,41). Interestingly, recent studies have
demonstrated that b2m fibrils, rather than the monomeric
protein, are highly membrane-active and putative toxic
substances (11). Here, we focus on membrane interactions
of short (weight average length <400 nm) b2m fibrils
formed by controlled fragmentation of their initially longer
counterparts (11,13). In particular, we describe the effects
of polyphenols including the widely-studied fibrillation
modulators EGCG and resveratrol (42), as well as the
synthetic dye bromophenol blue and a second group of
compounds consisting of glycosaminoglycans heparin and
its building subunit heparin disaccharide (43), upon mem-
brane interactions of b2m fibrils. Furthermore, we examine
whether these two distinct classes of molecules exhibit
different effects upon membrane interactions of these
fibrils.MATERIALS AND METHODS
Materials
Chicken egg PC (L-a-phosphatidylcholine), chicken egg PG (L-a-phos-
phatidylglycerol), and NBD-PE (1,2-dipalmitoyl-sn-glycero-3-phosphoe-
thanolamine-n-(7-nitro-2-1,3-benzoxadiazol-4-yl), ammonium salt) were
purchased from Avanti Polar Lipids (Alabaster, AL).Biophysical Journal 105(3) 745–755TMA-DPH (1-(4-trimethyl ammonium phenyl)-6-phenyl-1,3,5-hexa-
triene), Laurdan (6-dodecanoyl-2-dimethylaminonaphthalene), and TMR
(5-(and-6)-carboxytetramethyl-rhodamine) were purchased from Molecu-
lar Probes (Eugene, OR).
Heparin from porcine intestinal mucosa (sodium salt, grade I-A),
heparin disaccharide I-A (sodium salt), EGCG (()-epigallocatechin
gallate,R95%), bromophenol blue, and resveratrol (R99%) were obtained
from Sigma-Aldrich (St. Louis, MO). Polymeric chains of full-length heparin
supplied by Sigma-Aldrich can range from 18 to 90 monomers (6–30 kDa),
whereas the majority of the chains contain 51–57 monomers (17–19 kDa).Preparation of fibril samples
Fibrils of wild-type human b2m were formed from recombinant protein as
previously described in Xue et al. (11). Briefly, lyophilized protein was dis-
solved in a fibril growth buffer containing 10 mM monosodium phosphate
and 50 mM NaCl, pH 2.0, and was syringe-filtered through a 0.2-mm pore
size filter. The protein concentration was adjusted to 120 mM and the solu-
tion was seeded with 0.1% (w/w) of fragmented b2m fibrils formed under
the same conditions, followed by incubation at 25C under quiescent con-
ditions for 48 h. This procedure was shown to result in formation of long
straight b2m fibrils (11). A quantity of 500 mL aliquots of the fibril suspen-
sions was subsequently fragmented by stirring (1000 rpm, 25C for 48 h) on
a custom-made precision stirrer. Fragmented long straight fibrils exhibiting
a weight average length of <400 nm (11,13) were used in all experiments.
For confocal microscopy, b2m monomers were labeled by TMR as
described in the Supporting Material. TMR-labeled fibrils were prepared
by mixing unlabeled and labeled monomers such that the final preparation
contained 10% of TMR-bound monomer.Vesicle preparation
Vesicles consisting of egg PC and egg PG (1:1, molar ratio) were prepared
in a liposome buffer (50 mM HEPES, 110 mM NaCl, 1 mM EDTA, 0.02%
(w/v) NaN3, pH 7.4) at 2-mM total lipid concentration.
Large unilamellar vesicles
Large unilamellar vesicles (LUVs) were prepared by extruding the lipid
suspension through a 400-nm pore-size polycarbonate filter as described
in the Supporting Material.
Giant vesicles
NBD-PE (0.04%, molar ratio) was added to the lipid mixture for giant
vesicle (GV) visualization by confocal microscopy. GVs were prepared
using a rapid evaporation method (44). A quantity of 500 mL of aqueous
phase containing the liposome buffer supplemented with 0.1 M sucrose
was added to 200 mL of lipid-containing solution in chloroform in a
round-bottom flask, followed by brief vigorous mixing of the two phases
by pipetting. The organic solvent was immediately removed in a rotary
evaporator under reduced pressure (40 mbar) for 3 min at room tempera-
ture. The resulting vesicle solution exhibited a turbid appearance and was
used on the day of preparation.Vesicle disruption experiments in the presence
of small molecules and heparin
Aliquots from the fibril stock solution (120 mM monomer equivalent con-
centration) were mixed with the vesicles and fibril-membrane interactions
were assessed through various spectroscopy and microscopy techniques.
In each experiment fibrils were incubated for 3 min with the required
amount of the test compound in the liposome buffer before addition
to the vesicles using a b2m/test compound ratio of 1:0.4 (w/w) for GAGs
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EGCG, bromophenol blue or resveratrol). Stock solutions of the tested
small molecules and heparin were prepared in the buffer used for liposome
preparations except for resveratrol, which was dissolved in buffer/ethanol
2:1 (v/v). For the control experiments, corresponding amounts of freshly
prepared b2m monomer in the fibril-growth buffer, the fibril growth buffer
alone, or buffer/ethanol 2:1 mixture were used.Microscopy imaging
Fibrils preincubated in the liposome buffer alone or with test compounds for
3 min as described above were diluted 10-fold into the vesicle suspension,
yielding a 12 mM b2m monomer equivalent concentration and 1.8 mM total
lipid concentration at a final pH of 7.4. The images were obtained after
15-min incubation of the fibrils with the vesicles.
Confocal microscopy
Egg PC/PG/NBD-PE (1:1:0.0008 molar ratio) GVs and TMR-labeled b2m
fibrils were placed on a glass-bottom Petri dish (MatTek, Ashland, MA) and
imaged on an Axiovert 100M confocal laser scanning microscope (Carl
Zeiss, Jena, Germany) using a 63/1.4 N.A. Plan Apochromat DIC oil
immersion objective lens (Carl Zeiss). The NBD-PE fluorescent probe
was excited with the 488-nm line of an argon laser, while TMR fluorescence
was excited with argon-krypton laser at 568 nm. Long-pass (LP) filters LP
505 and LP 580 were employed for acquisition of NBD and TMR fluores-
cence, respectively.
Cryo-TEM
A drop of a sample solution containing egg PC/PG (1:1) LUVs incubated
with fibrils alone or in the presence of the different test compounds was
deposited onto a transmission electron microscope (TEM) 300-mesh
Cu grid coated with a holey carbon film (Lacey substrate; Ted Pella,
Redding, CA). Vitrification was achieved using an electron microscopy
(EM) Grid Plunger (Leica Microsystems, Buffalo Grove, IL). The samples
were examined at 180C using a Tecnai 12 G2 TWIN TEM (FEI,
Hillsboro, OR) equipped with a model No. 626 cold stage (Gatan, Warren-
dale, PA), and the images were recorded using a model No. 794 charge-
coupled device camera (Gatan) at 120 kV in low-dose mode.Liposome dye release assay
LUVswere prepared from egg PC/PG (1:1) as described above, except that a
buffered carboxyfluorescein (CF) solution (50 mM CF, 50 mM HEPES,
10 mMNaCl, 1 mMEDTA, 0.02% (w/v) NaN3, pH 7.4) instead of liposome
buffer was used. After the extrusion, the LUVswerewashed three timeswith
liposome buffer by centrifugation at 20,000 g and resuspension to yield a
stock solution of 0.5 mM total lipids. A quantity of 2.5 mL aliquots of these
LUVs was than diluted into liposome buffer and mixed with fibrils (with or
without test compounds as described above) to obtain a total sample volume
of 500mL and a final protein concentration (in terms of b2mmonomer equiv-
alent) of 3 mM. The vesicles are saturated by the b2m fibrils under these
experimental conditions because further increase of b2m concentration
does not affect the extent of LUVs leakage (11). Fluorescence emission of
carboxyfluorescein at 517 nm was then recorded for 15 min using an excita-
tionwavelength of 490 nmon a FL920 spectrofluorimeter (Edinburgh Instru-
ments, Edinburgh, Scotland, UK). The percent leakage was calculated as
% Leakage ¼

Isample  I0

ðI100  I0Þ ;
where I0 is the fluorescence intensity of liposomes alone and I100 is the fluo-
rescence intensity after addition of 10 mL of Triton X-100 (final concentra-
tion 0.4% (v/v)), which results in complete vesicle disintegration.Fluorescence anisotropy
The fluorescence probe TMA-DPH was incorporated into egg PC/PG (1:1)
LUVs at final concentration of 0.22% (molar ratio) by mixing the dye dis-
solved in tetrahydrofuran at 1 mg/mL with the vesicle stock (2 mM) and
incubating for 30 min at room temperature. The organic solvent comprised
0.2% (v/v) of the LUV stock solution. Fibrils alone or reacted with different
test compounds were combined with 2.5 mL aliquots of egg PC/PG/TMA-
DPH LUVs prediluted with liposome buffer to a total sample volume of
500 mL. The final protein concentration was 3 mM (b2m monomer equiva-
lent). TMA-DPH fluorescence anisotropy was measured at 431 nm using an
excitation at 360 nm on a FL920 spectrofluorimeter (Edinburgh Instru-
ments). Anisotropy values were automatically calculated by the spectroflu-
orimeter software. Standard deviation values were obtained from 10 repeats
of the anisotropy scans. Changes in anisotropy values (D anisotropy) were
calculated by subtracting the data for control samples (vesicles with the
fibril growth buffer or with the buffer containing the appropriative test
compound) from the corresponding fibril-induced anisotropy values.Laurdan fluorescence assay
Laurdan probe was dissolved in chloroform and added to the egg PC/PG
(1:1) lipid mixture at 0.5% molar ratio before evaporation of the organic
solvent. LUVs were then prepared as described above at 2 mM total lipid
concentration. A quantity of 2.5 mL aliquots of egg PC/PG/Laurdan LUV
stock solution was diluted by liposome buffer (pH 7.4) to a final sample vol-
ume of 500 mL, followed by addition of b2m fibrils alone or preincubated
with different test compounds at the ratios described above. The final pro-
tein concentration was 3 mM (b2m monomer equivalent). Laurdan emission
spectra were recorded over a time course of 20 min using excitation at
365 nm on a PTI QuantaMaster spectrofluorimeter (Photon Technology
International, Birmingham, NJ). Shift of emission maxima was quantified
by general polarization (GP) function (45),
GP ¼ ðIblue  IredÞðIblue þ IredÞ ;
where Iblue and Ired are emission intensities at 435 and 478 nm, respectively.
Changes in GP values (D GP) were calculated by subtracting the data forcontrol samples (vesicles with fibril growth buffer or with the buffer con-
taining the appropriative test compound) from the corresponding fibril-
induced GP values.RESULTS
Small molecules and heparin modulate fibril-
induced membrane permeabilization
The molecules selected for this study belong to two families
of well-known fibrillation modulators: polyphenols and
glycosaminoglycans (GAGs) (Fig. 1). Specifically, plant-
derived polyphenols EGCG and resveratrol were tested for
their impact on fibril-membrane interactions, while the
synthetic polyphenol bromophenol blue was employed for
comparison with these natural compounds. The glycosami-
noglycans heparin and heparin disaccharide (a minimal
repeat unit of heparin (43) lacking its fibrillation-modulating
activities (46)) were also examined. Heparin has been shown
to affect amyloid formation of a peptide derived from the
human prion protein, wherein aggregation was enhanced at
low GAG/protein ratios and inhibited at higher heparin con-
centrations (46). In addition, heparin, but not its disaccharide,Biophysical Journal 105(3) 745–755
FIGURE 1 Molecular structures of the compounds studied. Note that
both heparin polymer and its disaccharide subunit were used in the studies
described.
FIGURE 2 The effect of polyphenols and GAGs on b2m fibril-induced
vesicle leakage. Time-dependent increase in fluorescence reflecting leakage
of carboxyfluorescein from PC/PG (1:1) LUVs after incubation with b2m.
(A) Effects of polyphenols on fibril-induced dye-leakage. (Long dash) b2m
fibrils alone (no fibrillation modulators added); (short dash) b2m monomers
alone; (1–3) b2m fibrils incubated for 3 min with (1) EGCG, (2) bromophe-
nol blue, and (3) resveratrol. (B) Effects of GAGs on fibril-induced vesicle
leakage. (Long dash) b2m fibrils alone; b2m fibrils incubated for 3 min with
(4) heparin polymer; and (5) heparin disaccharide. (C) Effect of preincuba-
tion of vesicles with different additives on b2m-fibril induced membrane
leakage. (Shaded) b2m fibrils alone. (Solid) Fibrillation modulators incu-
bated with vesicles for 30 min before addition of fibrils. (Open) Fibrillation
modulators incubated with b2m fibrils for 3 min before addition to the ves-
icles. Percent leakage corresponds to the end-point of the kinetic curves
(see Fig. S3 in the Supporting Material).
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physical properties of the molecules used are summarized in
Table 1.
Fig. 2 depicts dye release experiments designed to
analyze permeation of large unilamellar vesicles (LUVs)
composed of PC/PG (1:1) by b2m fibrils, and the effect of
the tested compounds upon the membrane disruption
processes. The leakage experiments employed vesicle-
encapsulated carboxyfluorescein, which initially is weakly
fluorescent due to self-quenching at high concentration
(49). After vesicle disruption by membrane-active analytes,
dye leakage results in increased fluorescence emission. The
experiments depicted in Fig. 2 A (long dash) confirm that
the b2m fibrils created in vitro interact with lipid membranes
and induce membrane defects permeable for the water-TABLE 1 Physical properties of molecules used in this
study (61)
Compound pKa
LogD,
pH 7 LogP
Hydrogen bonds
Donors Acceptors
EGCG 7.755 0.25 0.57 0.6395 0.702 8 11
Bromophenol
blue
4.125 0.10 5.10 9.1715 1.046 2 5
Resveratrol 9.225 0.10 3.02 3.0245 0.267 3 3
Heparin
disaccharide
— — — 2–6 12–24
LogP is a partition coefficient of nonionized molecule between octanol and
water; LogD is octanol/water partition coefficient of ionized and neutral spe-
cies of a compound formed at a given pH. Total number of hydrogen bonds
in a molecule corresponds to the number of hydrogen acceptors. All data are
given for 25C.
Biophysical Journal 105(3) 745–755soluble fluorescent dye, consistent with previous results
(11). The b2m fibrils, however, do not induce complete
vesicle disintegration as evident from only partial mem-
brane leakage (Fig. 2 A). This effect can be ascribed to fibril
self-association at neutral pH (50), which presumably
reduces amount of the fibrils available for membrane bind-
ing. An additional factor that may limit dye release by the
fibrils includes nonhomogenic distribution of lipid composi-
tions within vesicle population (51). Addition of b2m mono-
mers did not result in vesicle leakage (Fig. 2 A, short dash),
underscoring the fact that the b2m monomers do not damage
the lipid bilayer, at least as judged at the concentrations and
solution/lipid conditions used.
Preincubation of the b2m fibrils with the three polyphe-
nols analyzed here (at weight-equivalent concentrations)
shows that the effect of EGCG and bromophenol blue on
membrane disruption by the fibrils differs significantly
from that of resveratrol. Specifically, both bromophenol
blue and EGCG inhibit the effect of fibrils on membrane
permeability, although not completely (Fig. 2 A, curves
1 and 2). Incubation of the fibrils with either EGCG or bro-
mophenol blue for more prolonged periods did not enhance
the inhibitory capacity of the polyphenols (see Fig. S1 in
the Supporting Material). Resveratrol, on the other hand,
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long-term extent of the vesicle leakage is slightly reduced
(Fig. 2 A, curve 3) as compared with fibrils alone. This
enhancement in the initial amplitude of membrane perme-
ability can be ascribed to resveratrol-membrane interactions
(52) that may alter lipid bilayer susceptibility to the b2m
fibrils. Indeed, binding of resveratrol to LUVs was verified
by changes in anisotropy of lipid-incorporated TMA-DPH
probe (data not shown).
Negative-stain EMconfirmed that the general morphology
of b2m fibrils was not affected by incubation with the poly-
phenols for 5 min (see Fig. S2). EM images, however, could
not rule out that subtle structural changes within the fibrils
contributed to the observed effects of the molecules tested.
The dye-leakage results suggest that bromophenol blue and
EGCG disfavor the formation of bilayer lesions by the b2m
fibrils, whereas resveratrol appears to have no inhibitory
effect on b2m fibril-induced impairment of membrane integ-
rity. Fig. 2 B similarly shows dramatic differences between
the effects of full-length heparin (curve 4) and heparin
disaccharide (curve 5) upon vesicle leakage induced by
b2m fibrils. Specifically, whereas interaction of full-length
heparin with b2m fibrils prevents lipid bilayer disruption by
these protein aggregates, heparin disaccharide had minor
effect on the ability of the fibrils to cause dye release from
the vesicles (Fig. 2 B).
Polyphenols are relatively hydrophobic molecules that
have been shown to interact with membranes in vitro (53)
and in vivo (52). Accordingly, studies conducted on
EGCG have shown that it can cross the blood-brain barrier
(52) and interact with model membranes without forming
pores in the bilayer (53). We also observed membrane activ-
ity of EGCG through an increase in anisotropy of the mem-
brane-incorporated fluorescent probe TMA-DPH in the
presence of this molecule (data not shown). To determine
whether EGCG and bromophenol blue inhibit the mem-
brane activity of b2m fibrils via insertion of these molecules
into the lipid bilayer and subsequent stabilization of the
membrane, rather than by altering membrane-fibril interac-
tions, the polyphenols were incubated with vesicles before
the addition of b2m fibrils. The results of these experiments
(Fig. 2 C and see Fig. S3) showed that 30-min preincubation
of the polyphenols with LUVs did not enhance their inhib-
itory activity. On the contrary, the ability of the polyphenols
to impair fibril-induced dye-leakage was attenuated
compared with preincubation of these molecules with b2m
fibrils. Further control experiments confirmed that the poly-
phenols did not induce any detectable dye-leakage in the
absence of fibrils even after the 30-min incubation with ves-
icles (data not shown). These findings suggest that EGCG
and bromophenol blue suppress association of the b2m
fibrils with the PC/PG lipid vesicles, presumably by seques-
tering their exposed hydrophobic regions. By contrast with
the action of the polyphenols, full-length heparin showed
complete inhibition of membrane permeabilization by thefibrils. This effect occurred whether or not heparin was
preincubated with vesicles or with the fibrils (Fig. 2 C),
implying rapid binding of this molecule to b2m fibrils.Fibril-induced lipid bilayer deformation
and impact of fibril modulators
The vesicle dye-leakage experiments shown in Fig. 2 report
on the permeability of the lipid bilayer after incubation with
b2m fibrils. To examine the effects of fibrils on the bilayer
integrity, giant vesicles (GVs) composed of PC/PG (1:1)
incorporating the fluorescent probe NBD-PE (green) were
mixed with b2m fibrils containing rhodamine-labeled mono-
mer (red) (see Materials and Methods). Imaging of the sam-
ples using dual-color fluorescence confocal microscopy
allows simultaneous analysis of vesicle deformation (such
as shape change and bilayer perturbation), as well as the
behavior and localization of the b2m fibrils relative to the
lipids. Representative images depicting the experiments
are shown in Fig. 3, while quantification of the data is sum-
marized in Fig. S4 and Table S1 in the Supporting Material.
The images obtained reveal a smooth, round shape of
the GVs that is unperturbed after incubation with buffer or
with monomeric b2m (Fig. 3, A and B, respectively), consis-
tent with previous results (11,54). Images of the fibrils in the
absence of vesicles show evidence for extensive fibril clus-
tering at the pH used (pH 7.4) (Fig. 3 C). b2m fibrils formed
at pH 2 tend to bundle through lateral association when
transferred to a higher pH (50), presumably due to the
reduced positive charge. The fluorescence images shown
in Fig. 3 D, (i) and (ii), provide a striking visual depiction
of the effects of b2m fibrils that destroy the integrity of
the GVs, consistent with previous results (54). Furthermore,
the b2m fibril aggregates (displaying the red rhodamine
fluorescence) are coated by a thin layer composed of disas-
sembled lipids (exhibiting green fluorescence) that appear to
be extracted from the damaged vesicles. The confocal
microscopy images in Fig. 3 D thus reveal significant
vesicle disruption, consistent with extensive leakage of
carboxyfluorescein from LUVs prepared from the same
lipid composition (Fig. 2).
The confocal microscopy images presented in Fig. 3,
E–G, show the effect of preincubating the b2m fibrils
with EGCG, bromophenol blue, or resveratrol before their
addition to the liposomes. The results show that EGCG
impairs b2m-membrane interactions, giving rise to less
abundant vesicle destruction compared with GVs incubated
with b2m fibrils alone (compare Fig. 3, E and D(ii)). Quan-
titative analysis assessing ~100 vesicles in each sample (see
Table S1) demonstrated that EGCG reduced the extent of
fibril-damaged GVs by approximately five times from 65
to 12% (see Fig. S4). Preincubation of the fibrils with bro-
mophenol blue also resulted in only moderate GV disruption
(17% of damaged vesicles, see Fig. S4), with some vesicles
remaining intact (Fig. 3 F and see Fig. S4). Note thatBiophysical Journal 105(3) 745–755
FIGURE 3 Confocal fluorescence microscopy employing GVs contain-
ing NBD-PE (green) and b2m fibrils labeled with TMR (red). (A) Control
NBD-PE/PC/PG GVs; (B) GVs incubated with b2m monomers; (C)
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quenched in the sample containing b2m fibrils and bromo-
phenol blue (Fig. 3 F), due to fluorescence resonance energy
transfer between the emission spectrum of the fluorophore
and the absorbance of the polyphenol. To visualize fibrillar
aggregates in that sample, gain of the red channel has been
increased, resulting in residual NBD signal to become
visible as red fluorescence (Fig. 3 F).
In contrast with EGCG and bromophenol blue, which
appear to suppress b2m/vesicle interactions according to
the confocal microscopy data, resveratrol does not show a
significant effect on vesicle deformation caused by b2m
fibrils (Fig. 3 G and see Fig. S4), consistent with the finding
that resveratrol is relatively inefficient in inhibiting b2m-
induced LUVs disruption as judged by the carboxyfluor-
escein dye release experiments (Fig. 2 A). The confocal
images recorded after preincubation of the b2m fibrils
with heparin (Fig. 3 H) or heparin disaccharide (Fig. 3 I)
highlight considerable difference between the impacts of
these two compounds on the membrane activity of b2m
fibrils, corroborating the dye leakage results presented in
Fig. 2 B. Accordingly, preincubation of the fibrils with the
heparin polymer completely inhibited liposome disruption
with no vesicle damage visible (Fig. 3 H and see Fig. S4).
Binding of the full-length heparin to b2m fibrils also resulted
in the dispersion of the large fibril aggregates (Fig. 3 H)
without alteration of the overall fibrillar appearance (see
Fig. S2). Dispersed assemblies of the b2m fibrils exhibit
lower protein density and, as such, are not readily visible
using fluorescence confocal microscopy. In sharp contrast
with these results, heparin disaccharide did not inhibit
vesicle damage by b2m fibrils (Fig. 3 I and see Fig. S4),
echoing the dye-leakage experiments presented in Fig. 2 B.Visualizing fibril-vesicle interactions using
cryo-TEM
Cryogenic transmission electron microscopy (cryo-TEM)
analysis can provide further visual depiction of the interac-
tions of amyloid fibrils with lipid vesicles (54). This tech-
nique was used, therefore, to provide further insights into
the effects of the polyphenols and GAGs on these interac-
tions. Cryo-TEM images of LUVs created from PC/PG
(1:1) are shown in Fig. 4 A. In the absence of fibrils, the lipidTMR-b2m fibrils in pH 7.4 buffer. (D-I) (Left images) NBD-PE fluores-
cence (green); (middle) TMR fluorescence (red). (Right images) (D, i and
ii) Superimposition. GVs incubated with TMR-b2m fibrils. D(i) shows an
example of a single, large GV, enabling clear visualization of bilayer dam-
age. (Arrows, D ii) Examples of fibrillar aggregates coated by lipids that
were presumably derived from disintegrated vesicle(s). (E–I) b2m fibrils
preincubated with (E) EGCG, (F) bromophenol blue, (G) resveratrol, (H)
heparin, or heparin disaccharide (I) before mixing with GVs. Bars in all
images correspond to 20 mm. Note that residual NBD fluorescence is
detected in the red channel of the image presented in panel F such that
the NBD-labeled GVs appear red.
FIGURE 4 Cryo-TEM images of PGPG LUVs treated with fibrils and
different additives. (A) PC/PG (1:1) LUVs (control); (B) vesicles incubated
with b2m monomers; (C) vesicles incubated with b2m fibrils; (D–G) prein-
cubation of the b2m fibrils with (D) EGCG; (E) bromophenol blue; (F)
full-length heparin; and (G) heparin disaccharide before mixing with the
vesicles. Bars in all images correspond to 100 nm.
Inhibiting Amyloid-Membrane Interaction 751vesicles do not adhere readily to an EM grid and hence only
few vesicles are found in the control sample, with most of
them located in the vicinity of the hydrophobic carbon
mesh (Fig. 4 A). Vesicles treated with b2mmonomers appear
spherical and undamaged, similar to the control sample
(Fig. 4 B). Addition of b2m fibrils to the vesicles gave rise
to significant changes in liposome morphology and distribu-tion (Fig. 4 C). Accordingly, vesicles visibly accumulated in
the fibril-treated samples compared with images obtained of
LUVs alone. Moreover, the vesicles appear to associate with
the fibrils and to display significant perturbations to their
otherwise round shapes, corroborating previous findings
(54). Larger vesicles, in general, are more fragile than
smaller ones, and therefore GV deformation caused by
b2m fibrils is more substantial (Fig. 3 D) than the changes
to LUV shapes observed in Fig. 4 C. The cryo-TEM images
in Fig. 4, D and E, show the effects of the addition of EGCG
and bromophenol blue, respectively, on fibril-membrane
interactions. These polyphenols appear to reduce vesicle
deformation, consistent with the dye-leakage experiments
and confocal microscopy images presented above. Indeed,
in the presence of these small molecules, some vesicles
remain free of fibrils and mostly retain their round shapes.
The images of the heparin-treated fibril samples are even
more striking (Fig. 4 F). In these images LUVs accumula-
tion was not apparent and the vesicles appeared generally
unperturbed in morphology. Heparin disaccharide, by
contrast, had little effect on fibril-vesicle interactions; the
image in Fig. 4 G features aggregated and distorted vesicles
similar to the effects observed with the liposomes mixed
with b2m fibrils in the absence of this GAG.The effects of fibril binding on lipid dynamics
To investigate further the effect of the b2m amyloid fibrils
on membrane bilayer properties and the consequence
of preincubation with the fibril modulators, fluorescence
anisotropy of PC/PG (1:1) LUVs that incorporate the fluo-
rescence dye TMA-DPH was measured. The fluorescence
anisotropy of TMA-DPH fluorophore, which is oriented
perpendicular to the lipid bilayer plane (55), constitutes
a sensitive probe for bilayer fluidity and dynamics (56).
Fig. 5 A depicts the fluorescence anisotropy changes
induced by b2m fibrils and b2m fibril/test compound
mixtures upon addition to the TMA-DPH/PC/PG vesicles.
The results revealed that incubating the vesicles with b2m
monomers did not alter the TMA-DPH anisotropy, consis-
tent with the findings that b2m monomers have no effect
upon lipid membranes (Figs. 2–4).
By contrast, incubation of b2m fibrils with the TMA-
DPH/PC/PG vesicles gave rise to a pronounced increase
in anisotropy (Fig. 5 A, ii), indicating reduced bilayer
fluidity after binding of the membrane-active fibrils. The
effect of bromophenol blue, heparin, and heparin disac-
charide upon b2m fibril-induced changes in TMA-DPH
anisotropy are also depicted in Fig. 5 A, iii–iv (EGCG and
resveratrol gave rise to a significant increase in TMA-
DPH anisotropy when incubated with liposomes in the
absence of fibrils, ruling out measurements of their effects
on b2m-induced changes of lipid dynamics). These experi-
ments showed that preincubation of the fibrils with bro-
mophenol blue substantially lowered b2m fibril-inducedBiophysical Journal 105(3) 745–755
FIGURE 5 Modulation of bilayer fluidity by b2m amyloid fibrils and
different molecules. Changes in (A) fluorescence anisotropy of TMA-
DPH and (B) Laurdan emission shift (quantified by GP, Materials and
Methods) assayed within PC/PG (1:1) LUVs. The vesicles incubated with
(i) b2m monomers, (ii) b2m fibrils, (iii–v) b2m fibrils preincubated with
(iii) bromophenol blue, (iv) full-length heparin, and (v) heparin disaccha-
ride before mixing with the vesicles.
752 Sheynis et al.increase of lipid bilayer rigidity (Fig. 5 A, iii), consistent
with inhibition of fibril-lipids interactions in the presence
of this polyphenol.
Surprisingly, preincubating b2m fibrils with full-length
heparin did not attenuate the large increase in anisotropy
observed when the fibrils were incubated with liposomes
in the absence of any additives (Fig. 5 A, iv), despite the sub-
stantial evidence that heparin is able to protect LUVs and
GVs from fibril-induced disruption. Thus, the anisotropy
experiments suggest that heparin does not prevent the
binding of the b2m fibrils to the lipid bilayer, but instead
interferes with the ability of the fibrils to cause bilayer
disruption. Indeed, the cryo-TEM experiments depicted
above indicate that association of heparin-coated b2m fibrils
with lipid vesicles appears to be attenuated (Fig. 4 F) rela-
tive to the binding of the untreated fibrils (Fig. 4 C). Accord-
ingly, the image of the heparin/fibril mixture incubated with
LUVs shows depletion of lipid vesicles (Fig. 4 F), consistent
with impaired liposome-fibril interactions.
Addition of heparin disaccharide reduced the impact of
the b2m fibrils upon bilayer fluidity, as judged by TMA-
DPH anisotropy, but to a lesser extent than was observed
with bromophenol blue. The small heparin oligomer pre-
sumably interferes to some degree with membrane interac-
tions of b2m, but is not able to prevent bilayer disruption.
Changes in lipid bilayer fluidity after interactions with
b2m fibrils were also assessed using a different, comple-Biophysical Journal 105(3) 745–755mentary approach utilizing membrane-embedded Laurdan
as a probe of lipid dynamics (Fig. 5 B). The fluorescence
of Laurdan is sensitive to the polarity of the surrounding
medium and thus is blue-shifted in more rigid lipid environ-
ments due to exclusion of water molecules from the probe
proximity (45). The spectral shift is quantified using the
general polarization (GP) function (45), which is propor-
tional to the blue/red fluorescence ratio (Materials and
Methods). The results in Fig. 5 B corroborate the TMA-
DPH anisotropy data by demonstrating that b2m fibrils
induce an increase in GP values of Laurdan/PC/PG vesi-
cles. This change in GP remained largely unaltered after
preincubation of the b2m fibrils with full-length heparin,
reflecting a comparable reduction in lipid mobility in both
cases (Fig. 5 B and see Fig. S5). Bromophenol blue, by
contrast, largely blocked fibril-induced reduction of mem-
brane fluidity, whereas heparin disaccharide exhibited mar-
ginal effect on fibril-lipid interactions. The b2m monomer
did not affect lipid bilayer dynamics, confirming that the
monomeric protein is not membrane-active under the
conditions employed here, consistent with the TMA-DPH
anisotropy data.DISCUSSION
This study sheds light on an important question in the search
for therapeutic solutions to amyloid diseases, namely the
relationship between fibrillation modulators and the interac-
tions of amyloid fibrils with membranes in the presence of
these agents. Although the impact of inhibitors of amyloid
formation on the aggregation pathways of amyloidogenic
proteins has been studied extensively (27,29,57), the
possibility that the same compounds may disrupt fibril-
membrane interactions has not been investigated in depth
before, to our knowledge. Here we focus on the interaction
of in vitro-formed b2m amyloid fibrils with PC/PG (1:1)
lipid vesicles. We specifically chose b2m fibrils for this
study because these assemblies have been shown previously
to be cytotoxic and to be capable of permeabilizing lipid
membranes (11). Previous results have demonstrated that
electrostatic interactions are important determinants that
mediate membrane disruption by b2m fibrils because
increasing the fraction of negatively charged lipids within
model membranes significantly enhances lipid bilayer
permeabilization by these amyloid aggregates (11).
A recent study has revealed that interactions of frag-
mented b2m fibrils with model membranes give rise to
breakage or blebbing of the outer lipid leaflet, accompanied
by appearance of small vesicles associated with the fibrils
(54). These findings shed light on a possible mechanism
by which b2m fibrils elicit membrane permeabilization
and disruption. Small lipid structures (presumably vesicles
or micelles) have also been detected within other amyloid
protein systems during the fibrillation process in the pres-
ence of LUVs (58). Furthermore, previous results have
Inhibiting Amyloid-Membrane Interaction 753shown that the formation of b2m fibrils is not affected by
the small molecules examined here (59), whereas heparin
(but not heparin disaccharide) stabilizes fibrils against
depolymerization at physiological pH (47,48). Moreover,
the molecules tested in this study have all been shown
to have no detectable effect on fibril appearance (see
Fig. S2). Accordingly, for these fibril samples, at least,
modification of membrane interactions can be assessed
without interference from the effects of the small molecules
on fibril assembly.
The results presented demonstrate that b2m fibrils display
distinct abilities to interact with, and disrupt, membranes
when incubated with the different compounds assessed in
this study. Particularly intriguing is the observation that
incubation with small molecules belonging to similar struc-
tural and functional classes results in different membrane
interactions with b2m fibrils. Thus, although resveratrol
did not inhibit membrane interactions of b2m fibrillar aggre-
gates, EGCG and bromophenol blue hampered membrane
disruption, presumably by binding to the fibrillar aggregates
and impeding their association with lipid bilayer, rather than
by membrane stabilization mediated by the polyphenol
molecules themselves.
The potency of the three polyphenols tested here to pre-
vent lipid bilayer disruption is distributed in the following
order:
EGCG> bromophenol blue> resveratrol:
These differences can be attributed to the distinct structural
properties of the assessed compounds. EGCG, the most effi-
cient inhibitor among the three polyphenols, has a pKa value
of 7.75 (Table 1). At the pH used in this study (pH 7.4), a
significant fraction of EGCG molecules is negatively
charged, which presumably mediates favorable electrostatic
interactions with b2m fibrils. Resveratrol, which did not
alter lipid interactions of the fibrils, has a higher pKa of
9.15 (Table 1), remaining nonionized under the same condi-
tions. Further examination of the structures reveals that
EGCG can form the largest number of hydrogen bonds of
the three polyphenol compounds studied (11 bonds, Table 1),
whereas resveratrol is able to make only three such bonds.
Bromophenol blue, which demonstrated moderate inhibi-
tory activity on membrane interactions of b2m fibrils, is
fully charged at pH 7.4 (pKa 3.5, Table 1); however, this
molecule can form an intermediate amount of hydrogen
bonds (five bonds, Table 1) compared with the other poly-
phenols studied here. EGCG is also the most hydrophilic
polyphenol examined, as judged by its low partition coeffi-
cient between octanol and water (LogD, Table 1). Together,
these results suggest that electrostatic interactions and
hydrogen bonding, rather than hydrophobic forces per se,
are important determinants that govern the association of
the polyphenols with b2m fibrils and, thereby, attenuate
membrane disruption by these fibrillar aggregates. Whencomparing EGCG and bromophenol blue with a GAG
of similar molecular weight (heparin disaccharide), it is
evident that the latter failed to inhibit membrane activity
of b2m fibrils despite having a substantial number of nega-
tively charged substituents and potentially more hydrogen-
bond donors and acceptors than the polyphenols studied
here (Table 1). Our findings imply that a combination of
hydrophobic/aromatic interactions with electrostatic and
hydrogen bonds is required for sequestering b2m fibrillar
aggregates by these small molecules. Neither of these fac-
tors alone is sufficient to rationalize the effect of polyphe-
nols and heparin disaccharide on b2m fibrils-membrane
interactions.
Remarkable experimental outcomes were also found for
fibrils incubated with heparin and its building unit, heparin
disaccharide. Full-length heparin was found to be the most
powerful inhibitor of b2m fibril-induced damage of model
membranes among all of the compounds tested. Unlike
the small molecules, heparin abolished membrane disrup-
tion by b2m fibrils and was able to disperse the large fibrillar
aggregates observed at neutral pH. The inhibitory activity of
heparin can be ascribed to efficient binding of its multiple
negatively-charged sulfated and carboxylic units to b2m
fibrils that presumably impede their electrostatic interac-
tions with negatively charged lipids. The remarkable dif-
ference in inhibitory potency of heparin and heparin
disaccharide highlights the crucial role of the higher local
concentration of functional groups in promoting interactions
between the compound of interest and the b2m amyloid
fibrils. Thus, water-soluble polymers decorated by species
possessing the ability to suppress membrane damage by am-
yloid aggregates may provide a promising strategy in the
quest to design potent inhibitors of cell membrane disrup-
tion by amyloid fibrils. Interestingly in this regard, applica-
tion of polymeric compounds conjugated to functional
components such as fluorine or metal-chelating groups has
been shown to impair the amyloidogenesis and cytotoxicity
mediated by Ab peptide (34,37). Finally, and importantly,
comparison of the results of fluorescence spectroscopy
assays reporting upon lipid dynamics with those of mem-
brane damage, visualized by dye release, fluorescence mi-
croscopy, and cryo-TEM, suggests that heparin modulates,
rather than eliminates, b2m fibril-membrane association.
In conclusion, the spectroscopic and microscopic data
presented underscore the significant and divergent effects
of the different fibril modulators tested upon membrane
interactions of b2m fibrils. Additional studies are required
to assess whether our findings have a generic nature and
are pertinent to other amyloidogenic proteins. In light of
the emerging realization concerning the significance of
membrane interactions upon the pathological profiles in
protein misfolding diseases (3,19,60), the results suggest
that an important facet of any study to develop inhibitors
of amyloid diseases is the inclusion of analysis of the effect
of potential inhibitors on amyloid-lipid interactions.Biophysical Journal 105(3) 745–755
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